Mechanistically, the expression of RIPK3 was significantly upregulated by the natural secondary metabolite, trichothecin, and then RIPK3 enhanced the phosphorylation of MLKL and also activated the mitochondria energy metabolism and ROS production, leading to a novel strategy to sensitize cancer cells to cisplatin therapy [303]. Here, RIPK3 is linked to cancer.